https://m2.mtmt.hu/ hun 2026-09-23 06:34 JournalArticle 31896628 VALIDATED true Export Date: 13 July 2026; Cited By: 10; Correspondence Address: T. Tábi; Department of Pharmacodynamics, Semmelweis University, Budapest, Nagyvárad tér 4, 1089, Hungary; email: tabi.tamas@pharma.semmelweis-univ.hu; CODEN: NERED 0 false 2026-08-25T09:24:20.580+0000 2026-07-13T09:40:05.217+0000 2021-03-01T19:26:31.237+0000 true 10015206 Áncsán Gizella /api/admin/10015206 Admin Áncsán Gizella (SE admin) true 10015206 2026-07-13T09:40:05.082+0000 2021-11-29T09:12:53.493+0000 true 10080205 Szalóky-Siki Ágnes /api/admin/10080205 Admin Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Bagaméry, Fruzsina true true /api/journal/3344 REVIEWED NEUROCHEMICAL RESEARCH 0364-3190 1573-6903 true false 3344 false 3344 true 0364-3190 1573-6903 Journal FOREIGN 46 6 1350 1358 1350 9 2021 Funding 2008349 /api/funding/2008349 (2018-1.3.1-VKE-2018-00030) false true Funding 2008350 /api/funding/2008350 (Open access funding of Semmelweis University) false true true 2021 true true true false true false NONE 2026-08-25 false 10 0 10 8 2 10 10 9 6 9 9 7 7 8 2 0 10 8 10 8 0 2 2 Folyóiratcikk Journal Article 24 10 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2023 0 2 2 2 2 2024 0 1 1 1 1 2025 0 4 2 4 2 2026 0 3 3 3 3 Q2 false 10051361 false false false 2021-05-30T18:26:52.185+0000 Gyógyszerhatástani Intézet (SE / GYTK) 5 13 1 6 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 95603459 /api/authorship/95603459 Bagaméry, Fruzsina [Bagaméry, Fruzsina (gyógyszerészeti t...), szerző] Gyógyszerhatástani Intézet (SE / GYTK) 1 0.16666667 true false false Author 10051345 /api/author/10051345 Bagaméry Fruzsina (gyógyszerészeti tudományok) Bagaméry Fruzsina true 10051345 true Bagaméry Fruzsina true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 95603460 /api/authorship/95603460 Varga, Kamilla [Varga, Kamilla (Gyógyszerészet), szerző] Gyógyszerhatástani Intézet (SE / GYTK) 2 0.16666667 false false false Author 10077053 /api/author/10077053 Varga Kamilla (Gyógyszerészet) Varga Kamilla true true Varga Kamilla true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 95603461 /api/authorship/95603461 Kecsmár, Kitti 3 0.16666667 false false false Kecsmár Kitti true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 95603462 /api/authorship/95603462 Vincze, István [Vincze, István (gyógyszerészeti), szerző] Gyógyszerhatástani Intézet (SE / GYTK) 4 0.16666667 false false false Author 10051361 /api/author/10051361 Vincze István (gyógyszerészeti) Vincze István true 10051361 true Vincze István true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 95603463 /api/authorship/95603463 Szökő, Éva [Szökő, Éva (Farmakológia, gyó...), szerző] Gyógyszerhatástani Intézet (SE / GYTK) 5 0.16666667 false false false Author 10003174 /api/author/10003174 Szökő Éva (Farmakológia, gyógyszeranalitika) Szökő Éva true 10003174 true Szökő Éva true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 95603464 /api/authorship/95603464 Tábi, Tamás ✉ [Tábi, Tamás (Farmakológia), szerző] Gyógyszerhatástani Intézet (SE / GYTK) 6 0.16666667 false true true Author 10012548 /api/author/10012548 Tábi Tamás (Farmakológia) Tábi Tamás true 10012548 true Tábi Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 18490609 /api/publicationidentifier/18490609 DOI: 10.1007/s11064-021-03269-2 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.1007/s11064-021-03269-2 https://doi.org/10.1007/s11064-021-03269-2 false true PublicationIdentifier 18531452 /api/publicationidentifier/18531452 WoS: 000620402400002 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000620402400002 https://www.webofscience.com/wos/woscc/full-record/000620402400002 true true PublicationIdentifier 18494440 /api/publicationidentifier/18494440 Scopus: 85101237454 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85101237454 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85101237454 false true PublicationIdentifier 18490611 /api/publicationidentifier/18490611 PubMed: 33616807 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 33616807 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33616807&dopt=Abstract false true PublicationIdentifier 20121671 /api/publicationidentifier/20121671 Google scholar: 779504317877894718 PlainSource 12 /api/publicationsource/12 Google scholar PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Google scholar http://scholar.Google.com/scholar?hl=en&lr=&cluster=@@@ true true 12 true IDENTICAL 779504317877894718 http://scholar.Google.com/scholar?hl=en&lr=&cluster=779504317877894718 true true SjrRating 11196235 /api/sjrrating/11196235 sjr:Q2 (2021) Scopus - Biochemistry NEUROCHEMICAL RESEARCH 0364-3190 1573-6903 150 0.49 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1303 /api/classificationexternal/1303 Scopus - Biochemistry true 1303 true Q2 DIRECT true true Reference 18690616 /api/reference/18690616 1. Crous-Bou M, Minguillon C, Gramunt N, Molinuevo JL (2017) Alzheimer’s disease prevention: from risk factors to early intervention. Alzheimers Res Ther 9(1):71. https://doi.org/10.1186/s13195-017-0297-z, DOI: 10.1186/s13195-017-0297-z 1 10.1186/s13195-017-0297-z false true Reference 18690617 /api/reference/18690617 2. Kullmann S, Heni M, Hallschmid M, Fritsche A, Preissl H, Haring HU (2016) Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans. Physiol Rev 96(4):1169–1209. https://doi.org/10.1152/physrev.00032.2015, DOI: 10.1152/physrev.00032.2015 2 10.1152/physrev.00032.2015 false true Reference 18690618 /api/reference/18690618 3. Santiago JCP, Hallschmid M (2019) Outcomes and clinical implications of intranasal insulin administration to the central nervous system. Exp Neurol 317:180–190. https://doi.org/10.1016/j.expneurol.2019.03.007, DOI: 10.1016/j.expneurol.2019.03.007 3 10.1016/j.expneurol.2019.03.007 false true Reference 18690619 /api/reference/18690619 4. Johnston AM, Pirola L, Van Obberghen E (2003) Molecular mechanisms of insulin receptor substrate protein-mediated modulation of insulin signalling. FEBS Lett 546(1):32–36. https://doi.org/10.1016/s0014-5793(03)00438-1, DOI: 10.1016/s0014-5793(03)00438-1 4 10.1016/s0014-5793(03)00438-1 false true Reference 18690620 /api/reference/18690620 5. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378(6559):785–789. https://doi.org/10.1038/378785a0, DOI: 10.1038/378785a0 5 10.1038/378785a0 false true Reference 18690621 /api/reference/18690621 6. Ishiguro K, Shiratsuchi A, Sato S, Omori A, Arioka M, Kobayashi S, Uchida T, Imahori K (1993) Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett 325(3):167–172. https://doi.org/10.1016/0014-5793(93)81066-9, DOI: 10.1016/0014-5793(93)81066-9 6 10.1016/0014-5793(93)81066-9 false true Reference 18690622 /api/reference/18690622 7. Leroy K, Boutajangout A, Authelet M, Woodgett JR, Anderton BH, Brion JP (2002) The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer’s disease. Acta Neuropathol 103(2):91–99. https://doi.org/10.1007/s004010100435, DOI: 10.1007/s004010100435 7 10.1007/s004010100435 false true Reference 18690623 /api/reference/18690623 8. Solano DC, Sironi M, Bonfini C, Solerte SB, Govoni S, Racchi M (2000) Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J 14(7):1015–1022. https://doi.org/10.1096/fasebj.14.7.1015, DOI: 10.1096/fasebj.14.7.1015 8 10.1096/fasebj.14.7.1015 false true Reference 18690624 /api/reference/18690624 9. Talbot K (2013) Brain insulin resistance in alzheimer disease and its potential treatment with a mediterranean diet and GLP-1 analogues. Psychiatr Times. https://doi.org/10.2337/dc12-2074), DOI: 10.2337/dc12-2074) 9 10.2337/dc12-2074) false true Reference 18690625 /api/reference/18690625 10. Talbot K, Wang HY (2014) The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer’s disease. Alzheimers Dement 10(1 Suppl):S12-25. https://doi.org/10.1016/j.jalz.2013.12.007, DOI: 10.1016/j.jalz.2013.12.007 10 10.1016/j.jalz.2013.12.007 false true Reference 18690626 /api/reference/18690626 11. de la Monte SM (2012) Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer’s disease. Drugs 72(1):49–66. https://doi.org/10.2165/11597760-000000000-00000, DOI: 10.2165/11597760-000000000-00000 11 10.2165/11597760-000000000-00000 false true Reference 18690627 /api/reference/18690627 12. Hoyer S, Muller D, Plaschke K (1994) Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism. J Neural Transm Suppl 44:259–268 12 false true Reference 18690628 /api/reference/18690628 13. Salkovic-Petrisic M, Hoyer S (2007) Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm Suppl 72:217–233 13 false true Reference 18690629 /api/reference/18690629 14. Takeda S, Sato N, Rakugi H, Morishita R (2011) Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function. Mol BioSyst 7(6):1822–1827. https://doi.org/10.1039/c0mb00302f, DOI: 10.1039/c0mb00302f 14 10.1039/c0mb00302f false true Reference 18690630 /api/reference/18690630 15. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers. J Clin Investig 122(4):1339–1353. https://doi.org/10.1172/jci57256, DOI: 10.1172/jci57256 15 10.1172/jci57256 false true Reference 18690631 /api/reference/18690631 16. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, Tweedie D, Perry T, Mattson MP, Kapogiannis D, Sambamurti K, Lahiri DK, Greig NH (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis 19(4):1205–1219. https://doi.org/10.3233/jad-2010-1314, DOI: 10.3233/jad-2010-1314 16 10.3233/jad-2010-1314 false true Reference 18690632 /api/reference/18690632 17. Li Y, Chigurupati S, Holloway HW, Mughal M, Tweedie D, Bruestle DA, Mattson MP, Wang Y, Harvey BK, Ray B, Lahiri DK, Greig NH (2012) Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS ONE 7(2):e32008. https://doi.org/10.1371/journal.pone.0032008, DOI: 10.1371/journal.pone.0032008 17 10.1371/journal.pone.0032008 false true Reference 18690633 /api/reference/18690633 18. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, Powers K, Shen H, Egan JM, Sambamurti K, Brossi A, Lahiri DK, Mattson MP, Hoffer BJ, Wang Y, Greig NH (2009) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 106(4):1285–1290. https://doi.org/10.1073/pnas.0806720106, DOI: 10.1073/pnas.0806720106 18 10.1073/pnas.0806720106 false true Reference 18690634 /api/reference/18690634 19. Qiu C, Wang YP, Pan XD, Liu XY, Chen Z, Liu LB (2016) Exendin-4 protects Abeta(1–42) oligomer-induced PC12 cell apoptosis. Am J Transl Res 8(8):3540–3548 19 false true Reference 18690635 /api/reference/18690635 20. Radenkovic M, Stojanovic M, Prostran M (2016) Experimental diabetes induced by alloxan and streptozotocin: The current state of the art. J Pharmacol Toxicol Methods 78:13–31. https://doi.org/10.1016/j.vascn.2015.11.004, DOI: 10.1016/j.vascn.2015.11.004 20 10.1016/j.vascn.2015.11.004 false true Reference 18690636 /api/reference/18690636 21. Like AA, Rossini AA (1976) Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science (New York, NY) 193(4251):415–417. https://doi.org/10.1126/science.180605, DOI: 10.1126/science.180605 21 10.1126/science.180605 false true Reference 18690637 /api/reference/18690637 22. Reaven GM, Ho H (1991) Low-dose streptozotocin-induced diabetes in the spontaneously hypertensive rat. Metabolism 40(4):335–337. https://doi.org/10.1016/0026-0495(91)90141-i, DOI: 10.1016/0026-0495(91)90141-i 22 10.1016/0026-0495(91)90141-i false true Reference 18690638 /api/reference/18690638 23. Wang Z, Gleichmann H (1998) GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes 47(1):50–56. https://doi.org/10.2337/diab.47.1.50, DOI: 10.2337/diab.47.1.50 23 10.2337/diab.47.1.50 false true Reference 18690639 /api/reference/18690639 24. Balogh M, Zádor F, Zádori ZS, Shaqura M, Király K, Mohammadzadeh A, Varga B, Lázár B, Mousa SA, Hosztafi S, Riba P, Benyhe S, Gyires K, Schäfer M, Fürst S, Al-Khrasani M (2019) Efficacy-Based Perspective to Overcome Reduced Opioid Analgesia of Advanced Painful Diabetic Neuropathy in Rats. Front Pharmacol 10:347. https://doi.org/10.3389/fphar.2019.00347, DOI: 10.3389/fphar.2019.00347 24 10.3389/fphar.2019.00347 false true Reference 18690640 /api/reference/18690640 25. Chen SR, Zhang J, Chen H, Pan HL (2019) Streptozotocin-Induced Diabetic Neuropathic Pain Is Associated with Potentiated Calcium-Permeable AMPA Receptor Activity in the Spinal Cord. J Pharmacol Exp Ther 371(2):242–249. https://doi.org/10.1124/jpet.119.261339, DOI: 10.1124/jpet.119.261339 25 10.1124/jpet.119.261339 false true Reference 18690641 /api/reference/18690641 26. Deshmukh M, Johnson EM Jr (1997) Programmed cell death in neurons: focus on the pathway of nerve growth factor deprivation-induced death of sympathetic neurons. Mol Pharmacol 51(6):897–906. https://doi.org/10.1124/mol.51.6.897, DOI: 10.1124/mol.51.6.897 26 10.1124/mol.51.6.897 false true Reference 18690642 /api/reference/18690642 27. Deng Y, Li B, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX (2009) Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer’s disease. Am J Pathol 175(5):2089–2098. https://doi.org/10.2353/ajpath.2009.090157, DOI: 10.2353/ajpath.2009.090157 27 10.2353/ajpath.2009.090157 false true Reference 18690643 /api/reference/18690643 28. Salkovic-Petrisic M, Tribl F, Schmidt M, Hoyer S, Riederer P (2006) Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J Neurochem 96(4):1005–1015. https://doi.org/10.1111/j.1471-4159.2005.03637.x, DOI: 10.1111/j.1471-4159.2005.03637.x 28 10.1111/j.1471-4159.2005.03637.x false true Reference 18690644 /api/reference/18690644 29. Genrikhs EE, Stelmashook EV, Golyshev SA, Aleksandrova OP, Isaev NK (2017) Streptozotocin causes neurotoxic effect in cultured cerebellar granule neurons. Brain Res Bull 130:90–94. https://doi.org/10.1016/j.brainresbull.2017.01.004, DOI: 10.1016/j.brainresbull.2017.01.004 29 10.1016/j.brainresbull.2017.01.004 false true Reference 18690645 /api/reference/18690645 30. Isaev NK, Genrikhs EE, Voronkov DN, Kapkaeva MR, Stelmashook EV (2018) Streptozotocin toxicity in vitro depends on maturity of neurons. Toxicol Appl Pharmacol 348:99–104. https://doi.org/10.1016/j.taap.2018.04.024, DOI: 10.1016/j.taap.2018.04.024 30 10.1016/j.taap.2018.04.024 false true Reference 18690646 /api/reference/18690646 31. Plaschke K, Kopitz J (2015) In vitro streptozotocin model for modeling Alzheimer-like changes: effect on amyloid precursor protein secretases and glycogen synthase kinase-3. J Neural Transm (Vienna, Austria: 1996) 122(4):551–557. https://doi.org/10.1007/s00702-014-1319-7, DOI: 10.1007/s00702-014-1319-7 31 10.1007/s00702-014-1319-7 false true Reference 18690647 /api/reference/18690647 32. Park J, Won J, Seo J, Yeo HG, Kim K, Kim YG, Jeon CY, Kam MK, Kim YH, Huh JW, Lee SR, Lee DS, Lee Y (2020) Streptozotocin Induces Alzheimer’s Disease-Like Pathology in Hippocampal Neuronal Cells via CDK5/Drp1-Mediated Mitochondrial Fragmentation. Front Cell Neurosci 14:235. https://doi.org/10.3389/fncel.2020.00235, DOI: 10.3389/fncel.2020.00235 32 10.3389/fncel.2020.00235 false true Reference 18690648 /api/reference/18690648 33. Biswas J, Gupta S, Verma DK, Singh S (2017) Streptozotocin alters glucose transport, connexin expression and endoplasmic reticulum functions in neurons and astrocytes. Neuroscience 356:151–166. https://doi.org/10.1016/j.neuroscience.2017.05.018, DOI: 10.1016/j.neuroscience.2017.05.018 33 10.1016/j.neuroscience.2017.05.018 false true Reference 18690649 /api/reference/18690649 34. Rajasekar N, Dwivedi S, Nath C, Hanif K, Shukla R (2014) Protection of streptozotocin induced insulin receptor dysfunction, neuroinflammation and amyloidogenesis in astrocytes by insulin. Neuropharmacology 86:337–352. https://doi.org/10.1016/j.neuropharm.2014.08.013, DOI: 10.1016/j.neuropharm.2014.08.013 34 10.1016/j.neuropharm.2014.08.013 false true Reference 18690650 /api/reference/18690650 35. Biswas J, Goswami P, Gupta S, Joshi N, Nath C, Singh S (2016) Streptozotocin Induced Neurotoxicity Involves Alzheimer’s Related Pathological Markers: a Study on N2A Cells. Mol Neurobiol 53(5):2794–2806. https://doi.org/10.1007/s12035-015-9144-z, DOI: 10.1007/s12035-015-9144-z 35 10.1007/s12035-015-9144-z false true Reference 18690651 /api/reference/18690651 36. Wang P, Jiang S, Cui Y, Yue Z, Su C, Sun J, Sheng S, Tian J (2011) The n-terminal 5-MER peptide analogue P165 of amyloid precursor protein exerts protective effects on SH-SY5Y cells and rat hippocampus neuronal synapses. Neuroscience 173:169–178. https://doi.org/10.1016/j.neuroscience.2010.10.069, DOI: 10.1016/j.neuroscience.2010.10.069 36 10.1016/j.neuroscience.2010.10.069 false true Reference 18690652 /api/reference/18690652 37. Bagamery F, Varga K, Kecsmar K, Vincze I, Szoko E, Tabi T (2020) Lack of insulin resistance in response to streptozotocin treatment in neuronal SH-SY5Y cell line. J Neural Transm 127(1):71–80. https://doi.org/10.1007/s00702-019-02118-5, DOI: 10.1007/s00702-019-02118-5 37 10.1007/s00702-019-02118-5 false true Reference 18690653 /api/reference/18690653 38. Xie HR, Hu LS, Li GY (2010) SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson’s disease. Chin Med J (Engl) 123(8):1086–1092 38 false true Reference 18690654 /api/reference/18690654 39. Kovalevich J, Langford D (2013) Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods Mol Biol 1078:9–21. https://doi.org/10.1007/978-1-62703-640-5_2, DOI: 10.1007/978-1-62703-640-5_2 39 10.1007/978-1-62703-640-5_2 false true Reference 18690655 /api/reference/18690655 40. Cheung YT, Lau WK, Yu MS, Lai CS, Yeung SC, So KF, Chang RC (2009) Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology 30(1):127–135. https://doi.org/10.1016/j.neuro.2008.11.001, DOI: 10.1016/j.neuro.2008.11.001 40 10.1016/j.neuro.2008.11.001 false true Reference 18690656 /api/reference/18690656 41. Tieu K, Zuo DM, Yu PH (1999) Differential effects of staurosporine and retinoic acid on the vulnerability of the SH-SY5Y neuroblastoma cells: involvement of bcl-2 and p53 proteins. J Neurosci Res 58(3):426–435, DOI: 10.1002/(SICI)1097-4547(19991101)58:3&lt;426::AID-JNR8&gt;3.0.CO;2-F 41 10.1002/(SICI)1097-4547(19991101)58:3&lt;426::AID-JNR8&gt;3.0.CO;2-F false true Reference 18690657 /api/reference/18690657 42. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254. https://doi.org/10.1006/abio.1976.9999, DOI: 10.1006/abio.1976.9999 42 10.1006/abio.1976.9999 false true Reference 18690658 /api/reference/18690658 43. Chapman CD, Schioth HB, Grillo CA, Benedict C (2018) Intranasal insulin in Alzheimer’s disease: Food for thought. Neuropharmacology 136(Pt B):196–201. https://doi.org/10.1016/j.neuropharm.2017.11.037, DOI: 10.1016/j.neuropharm.2017.11.037 43 10.1016/j.neuropharm.2017.11.037 false true Reference 18690659 /api/reference/18690659 44. Freiherr J, Hallschmid M, Frey WH 2nd, Brunner YF, Chapman CD, Holscher C, Craft S, De Felice FG, Benedict C (2013) Intranasal insulin as a treatment for Alzheimer’s disease: a review of basic research and clinical evidence. CNS Drugs 27(7):505–514. https://doi.org/10.1007/s40263-013-0076-8, DOI: 10.1007/s40263-013-0076-8 44 10.1007/s40263-013-0076-8 false true Reference 18690660 /api/reference/18690660 45. Jahn K, Wieltsch C, Blumer N, Mehlich M, Pathak H, Khan AQ, Hildebrandt H, Frieling H (2017) A cell culture model for investigation of synapse influenceability: epigenetics, expression and function of gene targets important for synapse formation and preservation in SH-SY5Y neuroblastoma cells differentiated by retinoic acid. J Neural Transm 124(11):1341–1367. https://doi.org/10.1007/s00702-017-1769-9, DOI: 10.1007/s00702-017-1769-9 45 10.1007/s00702-017-1769-9 false true Reference 18690661 /api/reference/18690661 46. Li D, Zhu B, Ding L, Lu W, Xu G, Wu J (2014) Role of the mitochondrial pathway in serum deprivation-induced apoptosis of rat endplate cells. Biochem Biophys Res Commun 452(3):354–360. https://doi.org/10.1016/j.bbrc.2014.08.054, DOI: 10.1016/j.bbrc.2014.08.054 46 10.1016/j.bbrc.2014.08.054 false true Reference 18690662 /api/reference/18690662 47. Eves EM, Xiong W, Bellacosa A, Kennedy SG, Tsichlis PN, Rosner MR, Hay N (1998) Akt, a target of phosphatidylinositol 3-kinase, inhibits apoptosis in a differentiating neuronal cell line. Mol Cell Biol 18(4):2143–2152. https://doi.org/10.1128/mcb.18.4.2143, DOI: 10.1128/mcb.18.4.2143 47 10.1128/mcb.18.4.2143 false true Reference 18690663 /api/reference/18690663 48. Lopez-Carballo G, Moreno L, Masia S, Perez P, Barettino D (2002) Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells. J Biol Chem 277(28):25297–25304. https://doi.org/10.1074/jbc.M201869200, DOI: 10.1074/jbc.M201869200 48 10.1074/jbc.M201869200 false true Reference 18690664 /api/reference/18690664 49. Ramalingam M, Kim SJ (2015) Insulin exerts neuroprotective effects via Akt/Bcl-2 signaling pathways in differentiated SH-SY5Y cells. J Recept Signal Transduct Res 35(1):1–7. https://doi.org/10.3109/10799893.2014.922576, DOI: 10.3109/10799893.2014.922576 49 10.3109/10799893.2014.922576 false true Reference 18690665 /api/reference/18690665 50. Talbot K (2014) Brain insulin resistance in Alzheimer’s disease and its potential treatment with GLP-1 analogs. Neurodegener Dis Manag 4(1):31–40. https://doi.org/10.2217/nmt.13.73, DOI: 10.2217/nmt.13.73 50 10.2217/nmt.13.73 false true Reference 18690666 /api/reference/18690666 51. Li Y, Bader M, Tamargo I, Rubovitch V, Tweedie D, Pick CG, Greig NH (2015) Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. J Neurochem 135(6):1203–1217. https://doi.org/10.1111/jnc.13169, DOI: 10.1111/jnc.13169 51 10.1111/jnc.13169 false true Reference 18690667 /api/reference/18690667 52. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH (2002) Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302(3):881–888. https://doi.org/10.1124/jpet.102.037481, DOI: 10.1124/jpet.102.037481 52 10.1124/jpet.102.037481 false true Reference 18690668 /api/reference/18690668 53. de Medeiros LM, De Bastiani MA, Rico EP, Schonhofen P, Pfaffenseller B, Wollenhaupt-Aguiar B, Grun L, Barbé-Tuana F, Zimmer ER, Castro MAA, Parsons RB, Klamt F (2019) Cholinergic Differentiation of Human Neuroblastoma SH-SY5Y Cell Line and Its Potential Use as an In vitro Model for Alzheimer’s Disease Studies. Mol Neurobiol 56(11):7355–7367. https://doi.org/10.1007/s12035-019-1605-3, DOI: 10.1007/s12035-019-1605-3 53 10.1007/s12035-019-1605-3 false true Reference 18690669 /api/reference/18690669 54. Agholme L, Lindström T, Kågedal K, Marcusson J, Hallbeck M (2010) An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimers Dis 20(4):1069–1082. https://doi.org/10.3233/jad-2010-091363, DOI: 10.3233/jad-2010-091363 54 10.3233/jad-2010-091363 false true /api/publication/31896628 Bagaméry Fruzsina et al. The Impact of Differentiation on Cytotoxicity and Insulin Sensitivity in Streptozotocin Treated SH-SY5Y Cells. (2021) NEUROCHEMICAL RESEARCH 0364-3190 1573-6903 46 6 1350-1358<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10051345"><a href="/gui2/?type=authors&mode=browse&sel=10051345" target="_blank">Bagaméry Fruzsina (<span class="authorship-author-name">Bagaméry Fruzsina</span> <span class="authorAux-mtmt"> gyógyszerészeti tudományok</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Gyógyszerhatástani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10077053"><a href="/gui2/?type=authors&mode=browse&sel=10077053" target="_blank">Varga Kamilla (<span class="authorship-author-name">Varga Kamilla</span> <span class="authorAux-mtmt"> Gyógyszerészet</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Gyógyszerhatástani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Kecsmár Kitti </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10051361"><a href="/gui2/?type=authors&mode=browse&sel=10051361" target="_blank">Vincze István (<span class="authorship-author-name">Vincze István</span> <span class="authorAux-mtmt"> gyógyszerészeti</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Gyógyszerhatástani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10003174"><a href="/gui2/?type=authors&mode=browse&sel=10003174" target="_blank">Szökő Éva (<span class="authorship-author-name">Szökő Éva</span> <span class="authorAux-mtmt"> Farmakológia, gyógyszeranalitika</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Gyógyszerhatástani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10012548"><a href="/gui2/?type=authors&mode=browse&sel=10012548" target="_blank">Tábi Tamás ✉ (<span class="authorship-author-name">Tábi Tamás</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Gyógyszerhatástani Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;31896628" target="_blank">The Impact of Differentiation on Cytotoxicity and Insulin Sensitivity in Streptozotocin Treated SH-SY5Y Cells</a></div> <div> <span class="journal-title">NEUROCHEMICAL RESEARCH</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/0364-3190">0364-3190</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1573-6903">1573-6903</a>)</span>: <span class="journal-volume">46</span> <span class="journal-issue">6</span> <span class="page"> pp 1350-1358 </span> <span class="year">(2021)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.1007/s11064-021-03269-2" target="_blank" href="https://doi.org/10.1007/s11064-021-03269-2"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000620402400002" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000620402400002"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85101237454" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85101237454"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="33616807" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33616807&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="779504317877894718" target="_blank" href="http://scholar.Google.com/scholar?hl=en&lr=&cluster=779504317877894718"> Google scholar </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Biochemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Cellular and Molecular Neuroscience&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q3</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 10</span> | Független: 8 | Függő: 2 | Nem jelölt: 0 | WoS jelölt: 9 | Scopus jelölt:&nbsp;6 | WoS/Scopus jelölt:&nbsp;9 | DOI jelölt:&nbsp;10 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;31896628&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 2 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 31896628</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (2018-1.3.1-VKE-2018-00030), (Open access funding of Semmelweis University) </div> <div class="lastModified">Utolsó módosítás: 2026.07.13. 11:40 Ruzsits Ágnes (SE_GYTK_Gyhatástan_Admin5_RÁ, admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Export Date: 13 July 2026; Cited By: 10; Correspondence Address: T. Tábi; Department of Pharmacodynamics, Semmelweis University, Budapest, Nagyvárad tér 4, 1089, Hungary; email: tabi.tamas@pharma.semmelweis-univ.hu; CODEN: NERED</pre> </div></div>